Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo F Fernandez

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Journal of Hematology & Oncology|October 8, 2010
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemiaJoseph Pidala, Jongphil Kim, Claudio Anasetti, et al.
British Journal of Haematology|September 17, 2013
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysisMohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, et al.
Cancer|July 1, 2011
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemiaJorge Cortes, Hagop Kantarjian, Edward D Ball, et al.
Leukemia Research|September 26, 2006
Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)Gail H Vance, Haesook Kim, Gary A Hicks, et al.
Leukemia Research|January 21, 2014
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failureMichael V Jaglal, Vu H Duong, Celeste M Bello, et al.
Leukemia & Lymphoma|March 6, 2020
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasiaElizabeth DiMaggio, Jun-Min Zhou, Ryan Caddell, et al.
British Journal of Haematology|June 19, 2021
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemiaPeter H Wiernik, Zhuoxin Sun, Larry D Cripe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myelomaNizar J Bahlis, Jennifer McCafferty-Grad, Ileana Jordan-McMurry, et al.
Blood|March 19, 2011
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinHugo F Fernandez, Zhuoxin Sun, Mark R Litzow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2020
Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host DiseaseChiara Frairia, Maura Nicolosi, Jamie Shapiro, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Journal of Hematology & Oncology|October 8, 2010
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemiaJoseph Pidala, Jongphil Kim, Claudio Anasetti, et al.
British Journal of Haematology|September 17, 2013
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysisMohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, et al.
Cancer|July 1, 2011
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemiaJorge Cortes, Hagop Kantarjian, Edward D Ball, et al.
Leukemia Research|September 26, 2006
Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)Gail H Vance, Haesook Kim, Gary A Hicks, et al.
Leukemia Research|January 21, 2014
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failureMichael V Jaglal, Vu H Duong, Celeste M Bello, et al.
Leukemia & Lymphoma|March 6, 2020
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasiaElizabeth DiMaggio, Jun-Min Zhou, Ryan Caddell, et al.
British Journal of Haematology|June 19, 2021
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemiaPeter H Wiernik, Zhuoxin Sun, Larry D Cripe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myelomaNizar J Bahlis, Jennifer McCafferty-Grad, Ileana Jordan-McMurry, et al.
Blood|March 19, 2011
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinHugo F Fernandez, Zhuoxin Sun, Mark R Litzow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2020
Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host DiseaseChiara Frairia, Maura Nicolosi, Jamie Shapiro, et al.
Pageof 6